Search
Bayer HealthCare Links
Clinical trials
Information about clinical studies is available at database of
News
-
2013-05-24 | Worldnews
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
2013-05-24 | Worldnews
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant more
-
2013-05-20 | Worldnews
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
2013-05-20 | Worldnews
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) more
-
2013-05-17 | Worldnews
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
2013-05-17 | Worldnews
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan
Bayer HealthCare has filed the oral investigational drug riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) for regulatory approval in Japan. more
-
2013-05-16 | Worldnews
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
2013-05-16 | Worldnews
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Bayer signed an agreement Thursday to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines. more
-
2013-05-16 | Cancer
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
2013-05-16 | Cancer
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types more





